Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
Open Access
- 1 June 1988
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 167 (6), 1811-1824
- https://doi.org/10.1084/jem.167.6.1811
Abstract
Soime EBV+ BL cell lines continue to grow as single cells on in vitro passage, show an unusually restricted expression of EBV-latent genes and retain a BL biopsy-like cell surface phenotype (group I/II lines); other change to growth in aggregates, show a broader pattern of virus latent gene expression, and develop a cell surface phenotype more characteristic of EBV-transformed LCL (group III lines). Here we show that the cell surface adhesion molecules LFA-1, ICAM-1, and LFA-3 are expressed at very low levels, if at all, on group I/II lines and are coordinately upregulated as BL lines move towards group III. The change to growth in aggregates reflects the increasing availability of LFA-1 and ICAM-1, the two ligands whose mutual interaction underlies homotypic BL cell adhesion in vitro. The low levels of ICAM-1 and LFA-3 on group I/IIBL cell lines are also associated with an impaired ability to interact with EBV-specific CTL in the antigen-independent phase of effector/target conjugation. mAb blocking studies show that the small number of conjugates that are formed with group I/II BL targets involve the LFA-1/ICAM-1 adhesion pathway but not the LFA-3 pathway; in contrast, both pathways contribute to the efficient conjugate formation shown by group III BL or LCL targets. Earlier work identified one group III line. WW1 BI, as unusual since it expressed the full spectrum of EBV-specific CTL. Here we show that this line has an anomalous pattern of adhesion molecule expression with high levels of LFA-1 and ICAM-1 in the absence of detectable LFA-3. The WW1 BL cells form conjugates with EBV-specific CTL through the LFA-1/ICAM-1 pathway, but in the absence of a target LFA-3/effector CD2 interaction these conjugates do not achieve target cell lysis. This may reflect an important role for target LFA-3 molecules in activating EBV-specific "CTL function. These in vitro studies, we postulate that downregulation of the adhesion molecules LFA-3 and ICAM-1 on EBV+ BL underlies the ability of the malignant clone to evade EBV-specific T cell surveillance in vivo.This publication has 25 references indexed in Scilit:
- ABSENCE OF CELL SURFACE LFA-1 AS A MECHANISM OF ESCAPE FROM IMMUNOSURVEILLANCEThe Lancet, 1987
- The Lymphocyte Function Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune SystemAnnual Review of Immunology, 1987
- LEUKOCYTE ADHESION DEFICIENCY: An Inherited Defect in the Mac-1, LFA-1, and p150,95 GlycoproteinsAnnual Review of Medicine, 1987
- Two antigen-independent adhesion pathways used by human cytotoxic T-cell clonesNature, 1986
- Epstein–Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillanceNature, 1985
- An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor proteinCell, 1984
- A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.The Journal of Experimental Medicine, 1983
- A human lymphocyte‐associated antigen involved in cell‐mediated lympholysisEuropean Journal of Immunology, 1983
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978
- Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virusInternational Journal of Cancer, 1968